Effective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone - PubMed (original) (raw)
Clinical Trial
doi: 10.1093/annonc/mdn551. Epub 2008 Aug 5.
Affiliations
- PMID: 18684695
- DOI: 10.1093/annonc/mdn551
Free article
Clinical Trial
Effective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone
B-S Kim et al. Ann Oncol. 2009 Jan.
Free article
Abstract
Background: Many patients with extranodal natural killer/T-cell lymphoma (NTCL) fail to the front-line therapy and need an effective second-line chemotherapy.
Patients and methods: This was single-institutional, phase II study. The primary end point was response rate and secondary end points were toxicity, time to treatment failure (TTF), and overall survival (OS). Patients with relapsed or refractory NTCL were eligible. They received the chemotherapy consisting of ifosfamide, methotrexate, etoposide, and prednisolone and it was repeated every 3 weeks.
Results: Thirty-two patients were enrolled and 15 patients had achieved partial remission (PR) or complete remission (CR) after the front-line chemotherapy. The International Prognostic Index scores were 0-1 in thirteen, 2 in five, 3 in five, and 4-5 in nine patients. Twelve and two patients achieved CR and PR, respectively. Median OS and TTF of all patients were 8.2 and 3.7 months, respectively. Non-hematologic toxic effects were well tolerated, but grade 3/4 leukopenia occurred in 11.7% of all cycles. Four patients developed febrile neutropenia and one patient died due to pneumonia.
Conclusions: This chemotherapy regimen was moderately effective for relapsed/refractory extranodal NTCL, nasal type. Toxic effects were moderate, but caution should be exercised to prevent severe infection.
Similar articles
- Ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) plus L-asparaginase as a first-line therapy improves outcomes in stage III/IV NK/T cell-lymphoma, nasal type (NTCL).
Kim M, Kim TM, Kim KH, Keam B, Lee SH, Kim DW, Lee JS, Jeon YK, Kim CW, Heo DS. Kim M, et al. Ann Hematol. 2015 Mar;94(3):437-44. doi: 10.1007/s00277-014-2228-4. Epub 2014 Oct 11. Ann Hematol. 2015. PMID: 25300500 - First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy +/- radiotherapy is active in stage I/II extranodal NK/T-cell lymphoma.
Lee KW, Yun T, Kim DW, Im SA, Kim TY, Yoon SS, Heo DS, Bang YJ, Park S, Kim BK, Kim NK. Lee KW, et al. Leuk Lymphoma. 2006 Jul;47(7):1274-82. doi: 10.1080/10428190600562823. Leuk Lymphoma. 2006. PMID: 16923557 - A phase II study of ifosfamide, methotrexate, etoposide, and prednisolone for previously untreated stage I/II extranodal natural killer/T-cell lymphoma, nasal type: a multicenter trial of the Korean Cancer Study Group.
Kim TM, Kim DW, Kang YK, Chung J, Song HS, Kim HJ, Kim BS, Lee JS, Kim H, Yang SH, Yuh YJ, Bae SH, Hyun MS, Jeon YK, Kim CW, Heo DS. Kim TM, et al. Oncologist. 2014 Nov;19(11):1129-30. doi: 10.1634/theoncologist.2014-0305. Epub 2014 Oct 3. Oncologist. 2014. PMID: 25280488 Free PMC article. Clinical Trial. - Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB. Hagemeister FB. Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. doi: 10.1007/s00280-002-0447-1. Epub 2002 Apr 12. Cancer Chemother Pharmacol. 2002. PMID: 12042984 Review. - Treatment of advanced extranodal NK/T cell lymphoma, nasal-type and aggressive NK-cell leukemia.
Suzuki R. Suzuki R. Int J Hematol. 2010 Dec;92(5):697-701. doi: 10.1007/s12185-010-0726-2. Epub 2010 Dec 1. Int J Hematol. 2010. PMID: 21116747 Review.
Cited by
- Treatment of extranodal NK/T-cell lymphoma: From past to future.
Yan Z, Yao S, Wang Z, Zhou W, Yao Z, Liu Y. Yan Z, et al. Front Immunol. 2023 Feb 7;14:1088685. doi: 10.3389/fimmu.2023.1088685. eCollection 2023. Front Immunol. 2023. PMID: 36825002 Free PMC article. Review. - High Pretreatment D-Dimer Levels Correlate with Adverse Clinical Features and Predict Poor Survival in Patients with Natural Killer/T-Cell Lymphoma.
Bi XW, Wang L, Zhang WW, Sun P, Yan SM, Liu PP, Li ZM, Jiang WQ. Bi XW, et al. PLoS One. 2016 Mar 31;11(3):e0152842. doi: 10.1371/journal.pone.0152842. eCollection 2016. PLoS One. 2016. PMID: 27032016 Free PMC article. - Primary NK/T cell lymphoma nasal type of the colon.
Mahuad CV, Bilbao ER, Garate GM, de Los Ángeles Vicente Repáraz M, Del Olmo M, Casali CÉ, Zerga ME, Chirife AM, Cicco JA. Mahuad CV, et al. Rare Tumors. 2013 Mar 11;5(1):e9. doi: 10.4081/rt.2013.e9. Print 2013 Feb 11. Rare Tumors. 2013. PMID: 23772308 Free PMC article. - IL-2Rα up-regulation is mediated by latent membrane protein 1 and promotes lymphomagenesis and chemotherapy resistance in natural killer/T-cell lymphoma.
Wang L, Bi XW, Zhu YJ, He YZ, Lai QY, Xia ZJ, Cai QQ. Wang L, et al. Cancer Commun (Lond). 2018 Oct 19;38(1):62. doi: 10.1186/s40880-018-0334-8. Cancer Commun (Lond). 2018. PMID: 30340635 Free PMC article. - Consolidative treatment after salvage chemotherapy improves prognosis in patients with relapsed extranodal natural killer/T-cell lymphoma.
Nie M, Bi XW, Zhang WW, Sun P, Xia Y, Liu PP, Huang HQ, Jiang WQ, Li ZM. Nie M, et al. Sci Rep. 2016 Apr 4;6:23996. doi: 10.1038/srep23996. Sci Rep. 2016. PMID: 27041507 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials